Selim Medical Press

Signal Management in Pharmacovigilance

From Detection and Validation to Benefit–Risk Decisions and Regulatory Action. This page holds the twenty-four editable toolkit files and the companion decision-support tool that accompany the book.

Dr. Hafez Selim, MD, PhD

The companion tool

Runs the book’s methods on your own numbers. Nothing is stored or transmitted.

One self-contained page. It makes no network request beyond loading itself, keeps no data, and can be saved and run offline. Every module carries a control that loads the book’s own worked example, so you can confirm the figures in the text before trusting it with your own.

The toolkit

24 editable files — 20 Word documents and 4 spreadsheets. Take one, or take the set. Each is explained in the Practical Tool section of the chapter listed, section N.5.

IDFileChapterPurpose
T-01 Signal Management SOP Outline DOCX 43 KB 4 A section-by-section skeleton for a signal management standard operating procedure, with the decision rights and interfaces each section must fix
T-02 Signal Detection Plan DOCX 42 KB 4 A product-level plan stating which sources are screened, by which method, at what frequency, by whom, and on what documented basis the frequency was set
T-03 Data-Source Inventory DOCX 41 KB 5 (also 27) A source-by-source record of what each data source can answer, what it must not be used for, its latency, and its known limitations
T-04 Clinical Alert Review Form DOCX 40 KB 7 (also 1) A structured single-case and small-series review capturing diagnostic specificity, latency, dechallenge and rechallenge, alternative causes, and outcome
T-05 Validation Checklist and Memo DOCX 43 KB 11 Separate fields for evidence supporting validation, evidence against, missing information, decision, reviewer, date, and escalation requirement
T-06 Prioritization Matrix and Scoring Worksheet XLSX 16 KB 12 The five-domain scale with its anchors, the total, the band, and a documented override field; scores and bands compute live
T-07 Signal Assessment Protocol DOCX 40 KB 13 A prespecified assessment plan: question in PICOTS form, definitions, sources, analyses, subgroups, sensitivity analyses, and the decision link
T-08 MedDRA Search and Case-Definition Worksheet DOCX 42 KB 6 The retrieval definition and the adjudication definition side by side, with drug roles, inclusion rules, and the selection flow with a count at every stage
T-09 Case-Series Line Listing Guide and QC Checklist DOCX 42 KB 14 Field specification for a line listing that shows pattern and exceptions together, with the quality-control checks applied before it is used
T-10 Time-to-Onset Analysis Plan DOCX 40 KB 9 Definition of the clock, handling of imputed intervals, summary statistics for a skewed distribution, and the prespecified sensitivity analyses
T-11 Disproportionality Calculation Worksheet XLSX 14 KB 8 Two-by-two entry with live PRR, ROR, IC, and IC₀₂₅ and their intervals, plus count-stability and masking panels
T-12 Observed-to-Expected Worksheet XLSX 11 KB 10 Live person-time, expected count, and observed-to-expected ratio with exact Poisson intervals, and a background-rate range panel
T-13 Totality-of-Evidence Table DOCX 40 KB 15 One row per evidence stream with direction, decision weight, and a reason referencing validity for the question rather than volume
T-14 Causal Reasoning Template DOCX 40 KB 16 Structured causal argument: supporting evidence, opposing evidence, alternative explanations and how each was tested, and an explicitly-not-supported field
T-15 Benefit–Risk Assessment Worksheet DOCX 41 KB 19 Qualitative benefit–risk table with a quantitative appendix for absolute-event estimates, subgroup analysis, and sensitivity scenarios
T-16 Committee Charter, Agenda, Pre-read, Minutes and Decision Log DOCX 44 KB 21 (also 2) Governance set for a signal management committee, including the one-page decision request and a minute format that records dissent
T-17 Signal Assessment Report, Closure Memo, Action Log and Reopening Review DOCX 42 KB 17 (also 18, 22) The assessment report, the closure memo with objective reopening triggers, the action log, and the record made when a trigger fires
T-18 Cross-Document Reconciliation Checklist DOCX 40 KB 23 Row-by-row reconciliation of one signal conclusion across the RMP, periodic reports, reference safety information, labeling, and study commitments
T-19 Inspection-Readiness Checklist DOCX 41 KB 24 Evidence-based readiness review of the signal management system, organized by what an inspector will ask to see and where it is held
T-20 KPI Dictionary and Dashboard Specification XLSX 13 KB 25 Nine-field dictionary entries with live numerator, denominator, and rate calculation, plus the unintended-incentive field for each indicator
T-21 AI Use-Case Validation and Oversight Checklist DOCX 41 KB 26 Intended use and exclusions, validation set and stratification, separate false-negative and false-positive tolerances, and named verification points
T-22 Special-Population Assessment Checklist DOCX 42 KB 10 Prompts for vaccines, pregnancy, oncology and rare disease, medication errors and misuse, and biologics and combination products
T-23 Signal Communication Checklist and Plain-Language Translation Exercise DOCX 41 KB 20 The seven required elements of a safety communication, with a paired exercise translating a technical conclusion into prescriber and patient language
T-24 Competency Self-Assessment and Professional Development Plan DOCX 41 KB 28 Five-domain self-assessment recorded against artifacts produced rather than activities attended, with an annual development plan

The four spreadsheets carry live formulas rather than static tables. T-11 and T-12 open on the book’s worked examples — the Velantor two-by-two and the NeuVax-7 observed-to-expected analysis — so you can verify the arithmetic in the text and then vary it.

Before you use any of it

Every template, scoring scheme, threshold, tier and timeline in these files is an illustrative company design. None is a regulatory requirement. Before any of them is issued inside a quality system it must be reconciled with the governing legislation in each region where the products are authorised, with the current guidance, and with the organization’s own procedures, and it must be approved through that organization’s document control.

The files are provided in editable form deliberately: they are drafting starting points, and a reader who does not change them has probably not read the chapter they belong to.

All products, patients and data in the book, the toolkit and the tool are fictional educational composites.

Regulatory content was last reviewed September 2026, including the replacement of FAERS by the FDA Adverse Event Monitoring System on 11 March 2026 and the deletion of the validated-signal notification under Article 21(2) of Commission Implementing Regulation (EU) 520/2012 by Regulation (EU) 2025/1466, in force 12 August 2025. Re-check against current guidance before relying on it.